Last reviewed · How we verify
HX301
At a glance
| Generic name | HX301 |
|---|---|
| Also known as | HX301 Monolactate Capsules |
| Sponsor | Hangzhou Hanx Biopharmaceuticals, Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study of HX301 in Patients with High-grade Giloma (PHASE1, PHASE2)
- The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors (PHASE1)
- Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies (PHASE1, PHASE2)
- Study of ON 123300 in Patients With Advanced Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HX301 CI brief — competitive landscape report
- HX301 updates RSS · CI watch RSS
- Hangzhou Hanx Biopharmaceuticals, Ltd. portfolio CI